Cipla Defeated In US Kyprolis Patent Tussle

Three Key US Patents Not Obvious, Court Finds

Indian firm Cipla went it alone against Amgen and its Onyx Therapeutics subsidiary to obtain a judgment that would allow for market entry in the US for the firm’s generic to the Kyprolis oncology brand. However, a district court has ruled in the main against the firm.

Gavel
Cipla has received a mainly negative verdict on three US Kyprolis patents • Source: Shutterstock

Cipla has suffered defeat in US patent-litigation proceedings with Amgen and its Onyx Therapeutics subsidiary over their Kyprolis (carfilzomib) injectable brand that is set to bar it from generic market entry until December 2027.

A US district court ruled against the Indian firm, finding that it had failed to prove by “clear and convincing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

The Politics Of Divisionals: How European Patentees Are Still Gaming The System

 
• By 

At Medicines for Europe’s legal affairs conference last month, divisional patents were once again a major subject of discussion. Attendees heard fresh details of how patentee games are preventing generics from hitting the market and restricting wider access to major medicines.

MSN Labs Swerves 2026 US Entresto Patent Ahead Of Separate July 15 Expiry

 
• By 

Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.

US Federal Circuit Says No To Teva And Viatris On Remanded Invega Sustenna Appeal

 
• By 

Just days after Viatris was frustrated in its attempts to challenge IP protecting Janssen’s Invega Trinza, the US Federal Circuit has rejected the firm’s and Teva’s bid to invalidate a patent shielding the one-month version of the brand, Invega Sustenna.

More from Generics Bulletin